Suchergebnisse - "Shah, Rashmi R"

PubPharm (10)

1

Safety of Novel Targeted Therapies in Oncology

enthalten in: Drug safety | 2019

von Shah, R. | Curigliano, G.

2

Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology

enthalten in: Drug safety | 2019

von Shah, R.

3

Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology

enthalten in: Drug safety | 2019

von Shah, R. | Shah, D.

4

Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology

enthalten in: Drug safety | 2019

von Curigliano, G. | Shah, R.

5

Repurposing old drugs in oncology : Opportunities with clinical and regulatory challenges ahead

enthalten in: Journal of clinical pharmacy and therapeutics | 2019

von Shah, R. | Stonier, P.

6

Hyperglycaemia Induced by Novel Anticancer Agents : An Undesirable Complication or a Potential Therapeutic Opportunity?

enthalten in: Drug safety | 2017

von Shah, R.

7

Comment on : Bono P, Oudard S, Bodrogi I, et al. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clin Genitourin Cancer 2016

enthalten in: Clinical genitourinary cancer | 2017

von Shah, R.

CommentOn: Clin Genitourin Cancer. 2016 Oct;14(5):406-414. - PMID 27287020

8

Effect of tyrosine kinase inhibitors on wound healing and tissue repair : implications for surgery in cancer patients

enthalten in: Drug safety | 2014

von Shah, D. | Dholakia, S. | Shah, R.

9

A fresh perspective on comparing the FDA and the CHMP/EMA : approval of antineoplastic tyrosine kinase inhibitors

enthalten in: British journal of clinical pharmacology | 2013

von Shah, R. | Roberts, S. | Shah, D.

10

Tyrosine kinase inhibitors : their on-target toxicities as potential indicators of efficacy

enthalten in: Drug safety | 2013

von Shah, D. | Shah, R. | Morganroth, J.

1
[1]